Wu M, Wang H, Wu X, Zeng H, Miao M, Song Y
J Hepatocell Carcinoma. 2025; 12:467-480.
PMID: 40061164
PMC: 11887506.
DOI: 10.2147/JHC.S500638.
Badran O, Cohen I, Bar-Sela G
Cancers (Basel). 2025; 16(24.
PMID: 39766056
PMC: 11674619.
DOI: 10.3390/cancers16244156.
Rodriguez R, Muller S, Colombeau L, Solier S, Sindikubwabo F, Caneque T
Chem Rev. 2025; 125(2):660-744.
PMID: 39746035
PMC: 11758815.
DOI: 10.1021/acs.chemrev.4c00577.
Schalk I
Nat Rev Microbiol. 2024; 23(1):24-40.
PMID: 39251840
DOI: 10.1038/s41579-024-01090-6.
Wu H, Fu M, Wu M, Cao Z, Zhang Q, Liu Z
Cell Death Dis. 2024; 15(8):553.
PMID: 39090116
PMC: 11294586.
DOI: 10.1038/s41419-024-06930-0.
Iron chelators: as therapeutic agents in diseases.
Salimi Z, Afsharinasab M, Rostami M, Eshaghi Milasi Y, Mousavi Ezmareh S, Sakhaei F
Ann Med Surg (Lond). 2024; 86(5):2759-2776.
PMID: 38694398
PMC: 11060230.
DOI: 10.1097/MS9.0000000000001717.
Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting.
Fontana F, Esser A, Egbulefu C, Karmakar P, Su X, Allen J
PLoS One. 2023; 18(12):e0293700.
PMID: 38117806
PMC: 10732420.
DOI: 10.1371/journal.pone.0293700.
Iron and copper: critical executioners of ferroptosis, cuproptosis and other forms of cell death.
Li Y, Du Y, Zhou Y, Chen Q, Luo Z, Ren Y
Cell Commun Signal. 2023; 21(1):327.
PMID: 37974196
PMC: 10652626.
DOI: 10.1186/s12964-023-01267-1.
Design and Synthesis of Poly(2,2'-Bipyridyl) Ligands for Induction of Cell Death in Cancer Cells: Control of Anticancer Activity by Complexation/Decomplexation with Biorelevant Metal Cations.
Balachandran C, Hirose M, Tanaka T, Zhu J, Yokoi K, Hisamatsu Y
Inorg Chem. 2023; 62(36):14615-14631.
PMID: 37642721
PMC: 10498496.
DOI: 10.1021/acs.inorgchem.3c01738.
Plant-derived chelators and ionophores as potential therapeutics for metabolic diseases.
Lee V, Janisse S, Heffern M
Chem Soc Rev. 2023; 52(11):3927-3945.
PMID: 37203389
PMC: 10281457.
DOI: 10.1039/d3cs00167a.
Reduced sulfatide content in deferoxamine-induced senescent HepG2 cells.
Ghislanzoni S, Sarcinelli G, Bresci A, Manetti F, Polli D, Tomassetti A
Int J Biochem Cell Biol. 2023; 159:106419.
PMID: 37086817
PMC: 10227190.
DOI: 10.1016/j.biocel.2023.106419.
Transferrin Receptor-Mediated Iron Uptake Promotes Colon Tumorigenesis.
Kim H, Villareal L, Liu Z, Haneef M, Falcon D, Martin D
Adv Sci (Weinh). 2023; 10(10):e2207693.
PMID: 36703617
PMC: 10074045.
DOI: 10.1002/advs.202207693.
β-catenin-IRP2-primed iron availability to mitochondrial metabolism is druggable for active β-catenin-mediated cancer.
Wu Y, Yang S, Han L, Shang K, Zhang B, Gai X
J Transl Med. 2023; 21(1):50.
PMID: 36703130
PMC: 9879242.
DOI: 10.1186/s12967-023-03914-0.
KLF14 regulates the growth of hepatocellular carcinoma cells via its modulation of iron homeostasis through the repression of iron-responsive element-binding protein 2.
Zhou H, Chen J, Fan M, Cai H, Dong Y, Qiu Y
J Exp Clin Cancer Res. 2023; 42(1):5.
PMID: 36600258
DOI: 10.1186/s13046-022-02562-4.
Engineering Alendronate-Composed Iron Nanochelator for Efficient Peritoneal Carcinomatosis Treatment.
Zhao J, Huang X, Liu P, Qiu M, Li B, Wen Y
Adv Sci (Weinh). 2022; 9(30):e2203031.
PMID: 36057999
PMC: 9596851.
DOI: 10.1002/advs.202203031.
Iron accumulation typifies renal cell carcinoma tumorigenesis but abates with pathological progression, sarcomatoid dedifferentiation, and metastasis.
Greene C, Attwood K, Sharma N, Balderman B, Deng R, Muhitch J
Front Oncol. 2022; 12:923043.
PMID: 35992801
PMC: 9389085.
DOI: 10.3389/fonc.2022.923043.
Detection of Ferritin Expression in Soft Tissue Sarcomas With MRI: Potential Implications for Iron Metabolic Therapy.
Petronek M, Tomanek-Chalkley A, Monga V, Milhem M, Miller B, Magnotta V
Iowa Orthop J. 2022; 42(1):255-262.
PMID: 35821920
PMC: 9210395.
Understanding the Potential and Risk of Bacterial Siderophores in Cancer.
Pita-Grisanti V, Chasser K, Sobol T, Cruz-Monserrate Z
Front Oncol. 2022; 12:867271.
PMID: 35785195
PMC: 9248441.
DOI: 10.3389/fonc.2022.867271.
An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells.
Fujisawa K, Takami T, Matsumoto T, Yamamoto N, Yamasaki T, Sakaida I
Cancer Metab. 2022; 10(1):8.
PMID: 35550011
PMC: 9103045.
DOI: 10.1186/s40170-022-00284-x.
The Iron-Inflammation Axis in Early-Stage Triple-Negative Breast Cancer.
Duan F, Zhong M, Ye J, Wang L, Jiang C, Yuan Z
Front Cell Dev Biol. 2022; 10:784179.
PMID: 35281097
PMC: 8904738.
DOI: 10.3389/fcell.2022.784179.
